Cardinal Health Reports $60.9 Billion Revenue with 11.3% Growth for Quarter Ended March 31, 2026

Cardinal Health, Inc. reported a total revenue of $60.9 billion for the three months ended March 31, 2026, marking an increase of 11.3% from $54.9 billion in the same period last year. The company's net earnings for the quarter were $399 million, a decrease from $506 million in the prior year, reflecting a net profit margin of approximately 0.7%. For the nine months ending March 31, 2026, total revenue reached $190.6 billion, up from $162.4 billion in the previous year, while net earnings were $1.3 billion, slightly down from $1.3 billion in the same period of fiscal 2025.

The financial performance was influenced by several strategic developments, including the acquisition of Solaris Health for approximately $1.9 billion, which was completed in November 2025. This acquisition is expected to enhance Cardinal Health's capabilities in the urology sector and is part of a broader strategy to expand its Pharmaceutical and Specialty Solutions segment. The company also reported transaction and integration costs associated with this acquisition amounting to $44 million for the nine months ended March 31, 2026. Additionally, Cardinal Health completed the acquisition of Advanced Diabetes Supply Group for $1 billion and a 73% ownership interest in GI Alliance for $2.8 billion, further solidifying its market position.

Operationally, Cardinal Health's Pharmaceutical and Specialty Solutions segment generated $56.1 billion in revenue for the quarter, up from $50.4 billion a year earlier. The Global Medical Products and Distribution segment reported revenue of $3.1 billion, slightly down from $3.2 billion. The company’s total assets increased to $56.7 billion as of March 31, 2026, compared to $53.1 billion at the end of the previous fiscal year. Cardinal Health's employee headcount remained stable at approximately 50,000, reflecting its commitment to maintaining operational efficiency amid ongoing acquisitions.

The company faced challenges, including a goodwill impairment charge of $184 million related to its Navista and Integrated Oncology Network reporting units, attributed to changes in the risk profile of its business plans. This impairment impacted the overall profitability for the quarter. Cardinal Health also reported a significant increase in cash provided by operating activities, totaling $3.5 billion for the nine months ended March 31, 2026, compared to $877 million in the prior year, driven by improved working capital management.

Looking ahead, Cardinal Health anticipates continued growth in its core segments, supported by recent acquisitions and strategic initiatives. The company remains focused on enhancing its service offerings and expanding its market share, particularly in the specialty pharmaceutical and medical products sectors. Cardinal Health's management expressed confidence in achieving operational efficiencies and maintaining a strong financial position as it navigates the evolving healthcare landscape.